Icahn School of Medicine at Mount Sinai Listed a New Clinical Trial to Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma (CC-220)

Press/Media

Period29 Sep 2022

Media coverage

1

Media coverage